AU4931693A - Ibuprofen-h2 antagonist combinations - Google Patents

Ibuprofen-h2 antagonist combinations

Info

Publication number
AU4931693A
AU4931693A AU49316/93A AU4931693A AU4931693A AU 4931693 A AU4931693 A AU 4931693A AU 49316/93 A AU49316/93 A AU 49316/93A AU 4931693 A AU4931693 A AU 4931693A AU 4931693 A AU4931693 A AU 4931693A
Authority
AU
Australia
Prior art keywords
ibuprofen
antagonist combinations
antagonist
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49316/93A
Inventor
Thomas N. Gates
Robert Mcmahon
Robert T Sims
William Slivka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Johnson and Johnson Consumer Inc
Original Assignee
Merck and Co Inc
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc, McNeil PPC Inc filed Critical Merck and Co Inc
Publication of AU4931693A publication Critical patent/AU4931693A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
AU49316/93A 1992-09-29 1993-09-21 Ibuprofen-h2 antagonist combinations Abandoned AU4931693A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95344092A 1992-09-29 1992-09-29
US953440 1992-09-29
PCT/US1993/008947 WO1994007541A1 (en) 1992-09-29 1993-09-21 Ibuprofen-h2 antagonist combinations

Publications (1)

Publication Number Publication Date
AU4931693A true AU4931693A (en) 1994-04-26

Family

ID=25493996

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49316/93A Abandoned AU4931693A (en) 1992-09-29 1993-09-21 Ibuprofen-h2 antagonist combinations

Country Status (6)

Country Link
EP (1) EP0663839A4 (en)
JP (1) JPH08502254A (en)
AU (1) AU4931693A (en)
CA (1) CA2144155A1 (en)
MX (1) MX9306006A (en)
WO (1) WO1994007541A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028988A1 (en) 1998-11-17 2000-05-25 Nitromed, Inc. Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
SE0000774D0 (en) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
DE60237087D1 (en) 2001-06-01 2010-09-02 Pozen Inc PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAID
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (en) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
CN101257800B (en) * 2005-07-18 2012-07-18 好利用医疗公司 Medicaments containing famotidine and ibuprofen
AU2007275360B2 (en) * 2006-07-18 2013-05-16 Horizon Medicines Llc Methods and medicaments for administration of ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
CA2956278C (en) 2008-01-04 2022-03-01 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine and applications thereof
EP2344139A1 (en) 2008-09-09 2011-07-20 AstraZeneca AB Method for delivering a pharmaceutical composition to patient in need thereof
EP2445499A4 (en) 2009-06-25 2013-02-27 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
BR112014016085A8 (en) 2011-12-28 2017-07-04 Pozen Inc Enhanced compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2015163832A1 (en) * 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
CN116194102A (en) 2020-07-15 2023-05-30 沙巴研究联合有限责任公司 Unit oral dosage composition comprising ibuprofen and famotidine for treating acute pain and reducing the severity and/or risk of heartburn

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1398A (en) * 1981-09-04 1987-12-18 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
IN171746B (en) * 1989-11-02 1992-12-26 Mcneil Ppc Inc
US4994604A (en) * 1990-01-10 1991-02-19 Merck & Co., Inc. Formation and resolution of ibuprofen lysinate
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC

Also Published As

Publication number Publication date
EP0663839A1 (en) 1995-07-26
MX9306006A (en) 1995-01-31
EP0663839A4 (en) 1998-06-03
WO1994007541A1 (en) 1994-04-14
CA2144155A1 (en) 1994-04-14
JPH08502254A (en) 1996-03-12

Similar Documents

Publication Publication Date Title
AU4166393A (en) Auto-reclosers
AU3561193A (en) TNF-muteins
AU3991693A (en) Pyrazinoindoles
AU6984494A (en) Antitussive
AU4931693A (en) Ibuprofen-h2 antagonist combinations
AU4177593A (en) Benzophenonehydrazones
AU4682293A (en) Ibuprofen-muscle relaxant combinations
AU685767B2 (en) Substituted benzazepinones
AU3042892A (en) Rockbolt
AU1556892A (en) 2-substituted-2-imidazolines
AU667580B2 (en) Line-handling block
AU1080292A (en) Ige-receptor-antibodies
AU4156393A (en) Heterocyclyltriazolinones
AU1766292A (en) Ibuprofen-decongestant combinations
AU664253B2 (en) Photo-deviometer
AU3461693A (en) Saddle-cloth
AU3562193A (en) Morpholin- and thiomorpholin-4-ylamides
AU5063493A (en) Fitting
AU2446192A (en) Mild soap-synbar
AU4164793A (en) Heterocyclyltriazolinones
AU4632493A (en) Weathershed
AU3185693A (en) Pyrrolylbenzodiazepinones
AU4864693A (en) Alkoxymethyl-substituted pyridonebiphenyls
AU2402392A (en) New anti-diarrheic agents
AU4703893A (en) Methanesulphonate